BlackRock
NMTC icon

BlackRock’s NeuroOne Medical Technologies NMTC Stock Holding History

BlackRock’s Portfolio NMTC Stock Details NMTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$76.4K Buy
+25,121
New +$103K ﹤0.01% 5070

Other funds holding NMTC

BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BA
Bard Associates Chicago, Illinois $451M AUM 66.6% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
BAM
Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return

BlackRock's NMTC Position: Q2 2026 in Review

BlackRock opened a new position in NeuroOne Medical Technologies (NMTC) in Q2 2026: 25,121 shares worth $76.4K. The stake represents ﹤0.01% of the portfolio and ranks #5070 among its holdings.

20 funds tracked by Wall St. Rank hold NMTC as of Q2 2026.

  • BlackRock held 25,121 shares of NeuroOne Medical Technologies worth $76.4K as of Q2 2026.
  • NeuroOne Medical Technologies was a new BlackRock position in Q2 2026.
  • NeuroOne Medical Technologies made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #5070 holding.
  • 20 funds tracked by Wall St. Rank held NeuroOne Medical Technologies as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.